Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
Axsome Therapeutics (NASDAQ: AXSM) said the first patient was dosed in its FOCUS-2 Phase 3 trial of solriamfetol for children with ADHD (ages 6 to <12). The randomized, double-blind, placebo-controlled study will enroll ~468 patients into two solriamfetol doses or placebo for 6 weeks; the primary endpoint is change in ADHD-RS-5 total score at week 6. The company also noted FOCUS-3 for adolescents.
How this was made
The 30-second read
Why it matters
First-patient dosing reduces “time-to-trial” uncertainty and can improve confidence in program continuity, but the trading catalyst is incremental until efficacy/safety data emerge.
Market read
This is a concrete clinical milestone (first patient dosed) that can modestly support AXSM sentiment, but it lacks data or regulatory timing updates.
What to watch
Key near-term risk is execution (enrollment speed, protocol adherence, and pediatric tolerability). The release also doesn’t update funding or expected NDA timing, limiting forward guidance value.
Background
Axsome previously announced FOCUS-3 in adolescents; FOCUS-2 extends solriamfetol’s Phase 3 evaluation to younger children (6 to <12).
Ticker impact
Axsome dosed the first patient in its FOCUS-2 Phase 3 trial of solriamfetol for children with ADHD, expanding the solriamfetol program.
Likely modest positive bias near-term; larger repricing would require enrollment pace updates or interim/final readouts.
The article discloses a concrete trial start (first patient dosed) plus key design details (age range, sample size, endpoints), but provides no results or regulatory timeline changes.
Market effects
Adds another pediatric ADHD Phase 3 datapoint for the CNS/psychiatry trial pipeline, reinforcing competitive activity around non-stimulant/novel mechanisms.
Primarily US biotech sentiment; no explicit regional demand or regulatory shift mentioned.
Trial is multicenter but the release is US-focused; global impact depends on later enrollment and eventual label strategy.
Counterpoint
A trial start is not the same as success; without enrollment pace, site activation, or early safety signals, the market may discount the milestone.
Key entities
- companyAxsome Therapeutics
Sponsor of the FOCUS-2 Phase 3 trial for solriamfetol in pediatric ADHD.
- drugSolriamfetol
DNRI/TAAR1 agonist/5-HT1A agonist being developed for ADHD and other CNS indications.
- clinical_trialFOCUS-2
Phase 3 randomized, double-blind, placebo-controlled trial in children aged 6 to <12 with ADHD; ~468 patients; primary endpoint at week 6 using ADHD-RS-5.
